{"transactions":[{"id":3169,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T21:29:58.000Z","date":"2026-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":4902,"price":9.32,"value":45686.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on September 16, 2024. The number of shares withheld was\ndetermined based on the closing price of the issuer's common stock on September 1, 2026."}],"balance_after":122815,"source":{"system":"sec-edgar","filing":"0001789335-26-000008","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789335/000178933526000008/primarydocument.xml","form_type":"4"}},{"id":788278,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-07T20:15:10.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":3167,"price":22.88,"value":72460.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025."}],"balance_after":3166,"source":{"system":"sec-edgar","filing":"0001789335-26-000006","document":"form4-05072026_080503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000178933526000006/form4-05072026_080503.xml","form_type":"4"}},{"id":823943,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-03-31T20:09:54.000Z","date":"2026-03-28","kind":"exercise","planned":false,"acquired":false,"shares":3166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":3167,"derivative":{"underlying":"Common Stock","underlying_shares":3166},"source":{"system":"sec-edgar","filing":"0001789335-26-000004","document":"form4-03312026_080349.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000178933526000004/form4-03312026_080349.xml","form_type":"4"}},{"id":823942,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-31T20:09:54.000Z","date":"2026-03-28","kind":"exercise","planned":false,"acquired":true,"shares":3166,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":6333,"source":{"system":"sec-edgar","filing":"0001789335-26-000004","document":"form4-03312026_080349.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000178933526000004/form4-03312026_080349.xml","form_type":"4"}},{"id":942987,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2026-01-08T21:33:39.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":39650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while\nthe optionee provides continuous service to the Issuer."}],"balance_after":39650,"derivative":{"exercise_price":14.18,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":39650},"source":{"system":"sec-edgar","filing":"0001789335-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590877/000178933526000002/primarydocument.xml","form_type":"4"}},{"id":942986,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-08T21:33:39.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":73749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and\nJanuary 6, 2030 while the recipient provides continuous service to the Issuer."}],"balance_after":127717,"source":{"system":"sec-edgar","filing":"0001789335-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590877/000178933526000002/primarydocument.xml","form_type":"4"}},{"id":1049189,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-03T20:47:46.000Z","date":"2025-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":4901,"price":8.93,"value":43765.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on September 16, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 29, 2025."}],"balance_after":53968,"source":{"system":"sec-edgar","filing":"0001562180-25-006078","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590877/000156218025006078/primarydocument.xml","form_type":"4"}},{"id":1105993,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T20:39:54.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 100% on the first anniversary of the date of grant, subject to the Eligible Director's continued service on such vesting date."}],"balance_after":20100,"derivative":{"exercise_price":4.47,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001578563-25-000324","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856325000324/primary_doc.xml","form_type":"4"}},{"id":1186024,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-02T00:06:11.000Z","date":"2025-03-28","kind":"exercise","planned":false,"acquired":false,"shares":3167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":6333,"derivative":{"underlying":"Common Stock","underlying_shares":3167},"source":{"system":"sec-edgar","filing":"0001578563-25-000204","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856325000204/primary_doc.xml","form_type":"4"}},{"id":1186023,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T00:06:11.000Z","date":"2025-03-28","kind":"exercise","planned":false,"acquired":true,"shares":3167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":3167,"source":{"system":"sec-edgar","filing":"0001578563-25-000204","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856325000204/primary_doc.xml","form_type":"4"}},{"id":1309732,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2025-01-06T21:59:14.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":62547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2026 while the optionee provides continuous service to the Issuer."}],"balance_after":62547,"derivative":{"exercise_price":7.86,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":62547},"source":{"system":"sec-edgar","filing":"0001562180-25-000187","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590877/000156218025000187/primarydocument.xml","form_type":"4"}},{"id":1403178,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2024-09-18T21:04:24.000Z","date":"2024-09-16","kind":"grant","planned":false,"acquired":true,"shares":289362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vesting commencement date shall be September 16, 2024. The options shall have a term of 10 years from the date of grant, subject to continuous service of the optionee to the Issuer. The options shall become exercisable as follows: with respect to 1/4th of the shares subject to the option when the optionee completes 12 months of continuous service to the Issuer after the vesting commencement date, and with respect to 1/48th of the shares subject to the option when the optionee completes each month of continuous service to the Issuer thereafter."}],"balance_after":289362,"derivative":{"exercise_price":12.74,"expiration_date":"2034-09-16","underlying":"Common Stock","underlying_shares":289362},"source":{"system":"sec-edgar","filing":"0001562180-24-006869","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590877/000156218024006869/primarydocument.xml","form_type":"4"}},{"id":1403177,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-18T21:04:24.000Z","date":"2024-09-16","kind":"grant","planned":false,"acquired":true,"shares":58869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock unit (RSU) award vesting commencement date shall be September 16, 2024. 1/4th of the shares subject to the RSU shall vest on each of the first, second, third and fourth anniversaries of the first day of the month in which the RSU was granted, subject to the continuous service of the recipient to the Issuer."}],"balance_after":58869,"source":{"system":"sec-edgar","filing":"0001562180-24-006869","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590877/000156218024006869/primarydocument.xml","form_type":"4"}},{"id":1433391,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-08-14T20:56:38.000Z","date":"2024-08-13","kind":"grant","planned":false,"acquired":true,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock upon the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":9500,"derivative":{"underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001578563-24-000369","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856324000369/primary_doc.xml","form_type":"4"}},{"id":1433390,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-14T20:56:38.000Z","date":"2024-08-13","kind":"grant","planned":false,"acquired":true,"shares":24600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":24600,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":24600},"source":{"system":"sec-edgar","filing":"0001578563-24-000369","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856324000369/primary_doc.xml","form_type":"4"}},{"id":1701933,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-21T21:01:43.000Z","date":"2023-12-20","kind":"grant","planned":false,"acquired":true,"shares":3334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option will vest in full on December 20, 2024, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":3334,"derivative":{"exercise_price":0.043,"exercise_date":"2024-12-20","expiration_date":"2033-12-20","underlying":"Common Stock","underlying_shares":3334},"source":{"system":"sec-edgar","filing":"0001628280-23-042490","document":"wk-form4_1703192494.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023042490/wk-form4_1703192494.xml","form_type":"4"}},{"id":2231131,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-15T20:23:08.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option will vest in full on June 14, 2023, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":0.441,"exercise_date":"2023-06-14","expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001578563-22-000021","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856322000021/primary_doc.xml","form_type":"4"}},{"id":2485070,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-04T01:44:41.000Z","date":"2021-12-01","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in three substantially equal installments on December 1, 2022, December 1, 2023 and December 1, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":1.87,"expiration_date":"2031-12-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001878930-21-000010","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000187893021000010/edgar.xml","form_type":"4"}},{"id":2788636,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-15T09:17:07.000Z","date":"2021-03-15","kind":"disposition_to_issuer","acquired":false,"shares":67500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."}],"balance_after":0,"derivative":{"exercise_price":2.84,"expiration_date":"2028-09-23","underlying":"Common Stock","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0000899243-21-011500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000089924321011500/doc4.xml","form_type":"4"}},{"id":2788635,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-15T09:17:07.000Z","date":"2021-03-15","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."}],"balance_after":0,"derivative":{"exercise_price":8.87,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-21-011500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000089924321011500/doc4.xml","form_type":"4"}},{"id":2788634,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-15T09:17:07.000Z","date":"2021-03-15","kind":"disposition_to_issuer","acquired":false,"shares":13000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."}],"balance_after":0,"derivative":{"exercise_price":15.84,"expiration_date":"2029-08-25","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0000899243-21-011500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000089924321011500/doc4.xml","form_type":"4"}},{"id":2788633,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-15T09:17:07.000Z","date":"2021-03-15","kind":"disposition_to_issuer","acquired":false,"shares":50056,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."}],"balance_after":0,"derivative":{"exercise_price":41.1,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":50056},"source":{"system":"sec-edgar","filing":"0000899243-21-011500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000089924321011500/doc4.xml","form_type":"4"}},{"id":2788632,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-15T09:17:07.000Z","date":"2021-03-13","kind":"disposition_to_issuer","acquired":false,"shares":37500,"price":53,"value":1987500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the \"Merger Agreement\"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. (\"Purchaser\"), and for certain purposes, Horizon Therapeutics plc (\"Ultimate Parent\"), including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-011500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000089924321011500/doc4.xml","form_type":"4"}},{"id":3226214,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T16:47:26.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":50056,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant vests as to 25% of the shares on March 2, 2021 with the remainder vesting in equal installments every three months thereafter and ending on March 2, 2024."}],"balance_after":50056,"derivative":{"exercise_price":41.1,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":50056},"source":{"system":"sec-edgar","filing":"0001209191-20-016155","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000120919120016155/doc4.xml","form_type":"4"}}]}